Identification and functional analysis of a novel PRKAG2 mutation responsible for Chinese PRKAG2 cardiac syndrome reveal an important role of non-CBS domains in regulating the AMPK pathway  by Zhang, Bi-li et al.
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Background:  PRKAG2  gene  encodes  the  2 regulatory  subunit  of  AMP-activated  protein  kinase  (AMPK)
that  acts  as  a  sensor  of cellular  energy  status,  and  its germline  mutations  are  responsible  for PRKAG2  car-
diac  syndrome  (PCS).  The  majority  of missense  mutations  of  cystathionine  beta-synthase  (CBS)  domains
found  in  PCS  impair  the binding  activity  of  PRKAG2  to adenosine  derivatives,  and  therefore  lead  to
PRKAG2  function  impairment  and  AMPK activity  alteration,  resulting  in  a familial  syndrome  of  ventricu-
lar  preexcitation,  conduction  defects,  and  cardiac  hypertrophy.  However,  it  is unclear  about  the PRKAG2
mutation  in  the non-CBS  domain.  Here,  a Chinese  family  exhibiting  the  cardiac  syndrome  associated  with
a novel  heterozygous  PRKAG2  mutation  (Gly100Ser)  mapped  to  exon  3  encoding  a non-CBS  domain  is
described  and  the  function  of  this  novel  mutation  was investigated  in  vitro.
Methods:  The  PRKAG2  G100S  and  R302Q  mutations  were  constructed  by a  two-step  polymerase  chain
reaction  and  then  transfected  into  CCL13  cells by lentivirus  vectors.  Wild-type  PRKAG2  gene  transfection
was  used  as a negative  control.  PRKAG2  expression  was  determined  by  Western  blot.  Immunoﬂuores-
cence  was  used  to  localize  the intracellular  PRKAG2  proteins.  MTT  assay  was  performed  to  explore  the
effect  of  mutations  on cell  proliferation.  Periodic  acid-Schiff  staining  was  used for  detecting  glycogen
accumulation.  AMPK  concentration  was  measured  with  enzyme-linked  immunosorbent  assay.
Results:  Our  results  showed  neither  intracellular  localization  of  PRKAG2  nor  cell  growth  was  altered.  In
contrast,  PRKAG2  protein  expression  levels  were  signiﬁcantly  reduced  by  this mutation.  Furthermore,
PRKAG2-mediated  activity  of  AMPK  was  attenuated,  resulting  in  glycogen  metabolism  dysregulation.
These  ﬁndings  revealed  that non-CBS  domains  of PRKAG2  were  essential  to the  regulation  of AMPK
activity,  similar  to CBS.
Conclusions:  Our  study  ascribes  a crucial  regulatory  role to the  novel  PRKAG2  G100S  mutation,  and  reiter-
ates that  PCS  occurs  as  a consequence  of  AMPK  signaling  abnormality  caused  by PRKAG2  gene mutations.
© 2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroductionPRKAG2 cardiac syndrome (PCS) is a relatively rare autoso-
al  dominant genetic disease of the heart, typiﬁed by familial
ardiac genetic disease or sporadic cases. PCS patients are predis-
osed to the development of various cardiac clinical changes such
∗ Corresponding authors at: Department of Cardiovascular Diseases, Changhai
ospital, Second Military Medical University, 168 Changhai Road, Shanghai 200433,
hina. Tel.: +86 21 3116 1255; fax: +86 21 3116 1248.
E-mail address: zhengxing57530@163.com (X. Zheng).
1 Co-ﬁrst authors.
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.04.010as ventricular preexcitation, progressive conduction system dis-
ease, ventricular hypertrophy, and even sudden death as well as
muscular and skeletal lesions. Germline mutations in the PRKAG2
gene, which encodes the 2 subunit of AMP-activated protein
kinase (AMPK) and is located on chromosome 7p36.1, have been
identiﬁed in the majority of PCS patients. AMPK, a heterotrimeric
protein kinase composed of a catalytic subunit () and two reg-
ulatory subunits ( and ), acts as a sensor of cellular energy
status and is activated under conditions of energy depletion mani-
fested by increased cellular AMP  levels [1]. Dominant mutations of
PRKAG2 seldom occur in sporadic cases but appear relatively com-
mon  in family constellation. Identiﬁcation of PRKAG2 mutations in
vier Ltd. All rights reserved.
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amilies coupled with their functional analysis supports the notion
hat mutational PRKAG2 is a cause of PCS. Mutations recognized
hus far include His142Arg, Arg302Gln, His383Arg, Thr400Asn,
yr487His, Asn488Ile, Gln506Lys, Arg531Gly, Ser548Pro, and
nsLeu351 [2–10]. These mutations invariably cluster within the
ateman domain [the region deﬁned as the cystathionine beta-
ynthase (CBS) domains] of the PRKAG2 gene. The mutation
rg302Gln is most common among them in clinical isolates.
Studies in both cellular and murine models of PRKAG2 cardiac
yndrome have successfully demonstrated that PRKAG2-mediated
ardiomyopathy is a distinct type of glycogen storage disease
nvolving primarily the heart. Consistent with a causative role of
RKAG2 in PCS, heterozygous mice carrying a mutant PRKAG2
llele develop pathological cardiac changes resembling the human
enetic disorder. Several in vitro and in vivo studies suggest that PCS
s caused by increased AMPK activity [5,11]. Paradoxically, intro-
uction of several PRKAG2 mutants into mammalian CCL13 cells or
ver-expression of Arg302Gln and Arg531Gly mutations in trans-
enic mouse models can lead to a decrease or no change in AMPK
ctivity [12–15]. Furthermore, a study by Banerjee et al. shows
hat the PRKAG2 Thr400Asn mutation results in early activation
f myocardial AMPK, followed by depression, and then recovery to
ild-type levels [16]. Taken together, the above-mentioned stud-
es support the notion that dysregulation of AMPK activity (either
ctivating or inhibiting) contributes to the development of PCS.
owever, these studies are far from revealing the full functional
apacity of PRKAG2.
In the current study, we were surprised to ﬁnd a Chinese fam-
ly with a new missense mutation (Gly100Ser) in PRKAG2 gene.
ssociated with this mutation, the family manifests ventricular
reexcitation, severe conduction system abnormalities, and cardiac
ypertrophy, similar to Western families in phenotype. Interest-
ngly, this mutation is located in a non-CBS domain, different from
ll previously characterized mutations. We  further show that the
utation can result in excessive glycogen accumulation in cell
odels by expressing this mutant PRKAG2 gene, which can be
ttributed to reduced PRKAG2 protein expression and PRKAG2-
ediated activity of AMPK. Thus, these results reveal a novel role
f the non-CBS domain of PRKAG2 in the regulation of AMPK activ-
ty, and link the mutation in non-CBS domains to PCS for the ﬁrst
ime in a challenge to the dogma that gene mutations in CBS
omains are responsible for familial PRKAG2-mediated cardiomy-
pathy. The study provides the basis for further elucidation of the
olecular network that leads to development of PCS in the Chinese
opulation.
aterials and methods
tudy cohort
A Chinese family with ventricular preexcitation accompa-
ied with conduction abnormity and cardiac hypertrophy was
nvestigated. Another simple hypertrophic cardiomyopathy fam-
ly and 100 unrelated healthy individuals were studied as controls.
nformed consent was obtained from study participants. Family
embers were evaluated by a detailed history, physical exami-
ation, 12-lead electrocardiogram (ECG), ultrasound cardiogram,
nd dynamic ECG. The information on dead familial members was
btained by history-taking and consulting medical records. The
iagnosis of ventricular preexcitation was made on the basis of
 short PR interval (<120 ms), widened QRS interval (>110 ms),
nd abnormal initial QRS vector ( wave). Moreover, the diagnosis
f conduction system disease was ascertained owing to evidence
f sinus node dysfunction or atrioventricular block on ECG, as
escribed previously [3]. Cardiac hypertrophy was  diagnosed on
he basis of incrassate interventricular septum or ventricular wall,iology 62 (2013) 241–248
according to diagnostic criteria of hypertrophic cardiomyopathy
[17–19]. Clinical features of the family were summarized and pedi-
gree of family was drawn using Cyrillic 2.02 software. In addition,
serum creatine kinase levels of study participants were determined
by automatic biochemical analyzer.
Mutation analysis
Blood was  collected from each study individual and DNA was
extracted using Flexi Gene DNA kit (QIAGEN, Hilden, Germany). The
genomic structure and cDNA sequence of PRKAG2 were obtained
from the GenBank database (accession number: NM 016203) and
oligonucleotide primers were designed for exons 1–16. Ampliﬁca-
tions of 16 exons were performed by polymerase chain reaction
(PCR). The products of each PCR reaction were checked on 1.5%
sepharose and puriﬁed using the QIAquick PCR puriﬁcation kit
(QIAGEN). Direct sequencing reactions in both the sense and anti-
sense direction were performed on an ABI377 automatic sequencer
(Applied Biosystems, Foster City, CA, USA). Sequences were com-
pared with published genomic sequences of the PRKAG2 gene.
Construction of plasmids and expression in CCL13
The incomplete PRKAG2 cDNA clone (GenBank accession num-
ber BC068598), which presents N-end loss of 44 amino acids, was
obtained by purchase. The PRKAG2 gene sequence was designed
according to the known PRKAG2 gene sequence (GenBank acces-
sion number NM 016203). The full-length PRKAG2 gene was
acquired using the designed primers by PCR-based gene assem-
bly method. The PCR product was  cloned into TA cloning vector.
To introduce the G100S and R302Qmutations (designated GS and
RQ) into PRKAG2, a two-step polymerase chain reaction method
was used. PCR products (GS and RQ) and TA cloning vector con-
taining wild-type PRKAG2 gene (WT) were digested with MluI and
NdeI and subcloned into the lentivirus vector. The CCL13 cells (pro-
vided by Dr. Hua-mao Wang, University of Fudan) were cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10%
(v/v) fetal bovine serum. After being cultured for 24 h, CCL13 cells
were infected with LV-GS, LV-RQ, and LV-WT at a MOI  of 10. After
transfection, CCL13 cells stably expressing either G100S AMPK-2,
R302Q AMPK-2, or WT  were cultured as above. The expres-
sion of AMPK-2 was  checked by Western blotting using anti-2
antibodies.
Western blot analysis
Immunoblotting was  performed to detect the expression of
PRKAG2 in CCL13 cell lines infected by recombinant lentivirus.
CCL13/LV-WT, CCL13/LV-GS, and CCL13/LV-RQ cells were scraped
off and harvested. All cells were lysed in RIPA buffer [50 mM TrisC1,
50 mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 10 mM NaF, 0.4 mM ethylene
diamine tetraacetic acid (EDTA), pH 8.0, with leupeptin and apro-
tinin] and centrifuged at 12,000 × g for 10 minutes. Samples with
50 g of total protein were resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) on a 10% gel and transferred onto a
nitrocellulose (NC) membrane. The blot was  incubated with Tris
buffered saline with Tween (TBST) with 1:200 rabbit primary anti-
body against human PRKAG2 (ProteinTech Group, Inc., Chicago, IL,
USA), followed by the secondary horseradish peroxidase (HRP)-
conjugated anti-rabbit antibody (Santa Cruz Biotechnology Inc.,
Dallas, TX, USA). After washing, the bands were detected by
enhanced chemiluminescence (ECL) detection kit and imaged with
a Kodak ﬁlm (Rochester, NY, USA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an endogenous protein for
normalization.
f Card
I
p
W
a
s
s
h
T
i
a
f
w
ﬂ
i
E
s
b
a
(
t
A
i
c
p
s
z
c
c
T
b
W
t
m
s
b
i
e
i
a
a
c
A
d
P
w
w
b
aB.-l. Zhang et al. / Journal o
mmunoﬂuorescent cytochemistry
The 4% paraformaldehyde-ﬁxed cells were examined for the
resence of WT or mutant PRKAG2. Slides with cultured CCL13/LV-
T,  CCL13/LV-GS, and CCL13/LV-RQ cells were incubated for 1 h
t room temperature in blocking buffer that contained 1% bovine
erum albumin (BSA) and 0.1% Triton X-100 in phosphate buffered
olution (PBS). The cells were then incubated with rabbit anti
uman PRKAG2 poly antibody as primary antibodies (Protein-
ech) in PBS for 2 h at room temperature. Tetramethylrhodamine
sothiocyanate-conjugated anti-rabbit IgG was diluted 1:500 in PBS
nd used as the secondary antibody (KPL, Guildford, UK) incubated
or 30 minutes at room temperature. Slides and coverslips were
ashed three times in PBS, after which the cells were viewed by
uorescence microscope (Eclipse E 800; Nikon, Tokyo, Japan) and
maged with a Kodak ﬁlm.
nzyme-linked immunosorbent assay for AMPK concentration
CCL13/LV-WT, CCL13/LV-GS, and CCL13/LV-RQ cells were
eeded to 6-well microtiter plates at 2 × 105 cells/well and incu-
ated at 37 ◦C with 5% CO2 for 24 h. The media containing the AMPK
ctivator 5-aminoimidazole-4-carboxamide-1--d-ribofuranoside
AICAR) of two concentrations (0.5 mM,  or 2 mM)  was  exchanged
o each well 60 min  before the end of incubation, respectively.
fter various treatments, cells were lysed in situ using 0.3 ml  of
ce-cold lysis buffer [50 mM Tris/HCl (pH 7.2), 1 mM ethylene gly-
ol tetraacetic acid (EGTA), 1 mM EDTA, 50 mM NaF, 1 mM Na
yrophosphate, 1% [w/v] Triton X-100, 0.1 mM phenylmethane
ulphonyl ﬂuoride (PMSF), 1 mM dithiothreitol (DTT), 0.1 mM ben-
amidine, and 5 g/ml soybean trypsin inhibitor]. The lysates were
entrifuged (4 ◦C, 10 min, 21,000 × g) and the supernatants were
ollected for AMPK enzyme-linked immunosorbent assay (ELISA).
he concentrations of AMPK in supernatants were determined
y ELISA kit according to the manufacturer’s instructions (ADL,
ashington, USA). Brieﬂy, these assays employed the quantita-
ive sandwich enzyme immunoassay technique with biotinylated
onoclonal antibodies speciﬁc for AMPK. Standard controls and
amples (100 mL  of supernatant) and biotinylated monoclonal anti-
odies were simultaneously pipetted into the wells in triplicate and
ncubated for 1 h at 37 ◦C. After AMPK binding and washing, the
nzyme (streptavidin-peroxydase) was added to each well. After
ncubation and thorough washing to remove all unbound enzyme,
 substrate solution which was acting on the bound enzyme was
dded to induce a colored reaction product. The intensity of this
olored product is directly proportional to the concentration of
MPK present in the samples. The optical density of each well was
etermined by a microplate reader at 450 nm.
eriodic acid-Schiff staining for glycogen
Sterile slides were put into 24-well microtiter plates, one in each
ell. Then, CCL13/LV-WT, CCL13/LV-GS, and CCL13/LV-RQ cells
ere digested, counted and seeded to slides at 1 × 104 cells/well. To
e covered with 70% of cells, cells were deprived of serum for 12 h
nd then incubated with 1640 medium at 37 ◦C with 5% CO2 for 24 h.
Fig. 1. Pedigree of a Chinese PRKAG2 cardiac syndrome family. Squares indicate maliology 62 (2013) 241–248 243
Accumulated glycogen was measured after slides containing cells
were ﬁxed in 4% formaldehyde with 1% periodic acid and Schiff’s
(PAS) reagent (Sigma, St Louis, MO,  USA) as described previously
[20].
MTT assay for CCL13 cell proliferation
CCL13/LV-WT, CCL13/LV-GS, and CCL13/LV-RQ cells were
deprived of serum for 12 h and then exposed to the same con-
centration of AICAR (0.5 mmol/L) for 30 min, 90 min, and 24 h,
respectively. Proliferation was  then determined in triplicate with a
colorimetric nonradioactive, MTT  proliferation assay. After expo-
sure of CCL13 cells of every group to AICAR, 10 l MTT  reagent
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
5 mg/ml  in PBS; Sigma] was added and allowed to incubate at 37 ◦C
for 4 h. After the incubation, samples were placed in a microtiter
plate and the absorbance was read at 450 nm with an ELISA plate
reader.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD). Stu-
dent’s t-test for paired values was used to analyze data. p-Values
less than 0.05 were regarded as statistically signiﬁcant. All of the
analyses were performed using SPSS for Windows (version 10.0;
SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics of patients
A 4-generation family with 12 affected individuals diagnosed
as having Wolff–Parkinson–White syndrome, conduction system
disease, and/or hypertrophic cardiomyopathy was  studied (Fig. 1
and Table 1). Clinical presentation of symptomatic arrhythmias
of affected family members (7 males and 5 females) occurred
from age 16 to 41 years. Eight had asymmetrical ventricular sep-
tal hypertrophy with mean thickness 2.09 ± 0.98 cm and cardiac
hypertrophy did not cause left ventricular outﬂow tract obstruc-
tion (Fig. 2A and B). Eight had atrioventricular block or sinus
abnormality requiring permanent pacemaker implantation. Six had
ventricular preexcitation and 3 of them showed short PR interval
on ECG (Fig. 2C). Five had superventricular tachycardia (4 atrial
ﬁbrillation and 1 atrial tachycardia). Four showed cardiac dilation
and heart failure at the terminal stage of disease and 1 died sud-
denly when young. Serum creatine kinase levels were normal in all
affected family members.
Identiﬁcation of a novel PRKAG2 mutation
A previously undetected missense mutation, glycine (100) to
serine, in exon 3 of PRKAG2 was  identiﬁed and shown to be present
in 7 living affected individuals who  were more than 25 years
old and 2 family members of the fourth generation who were
less than 25 years old and asymptomatic (Fig. 3A). The mutation
results from guanine (G) substituted by adenine (A) at nucleotide
es, and circles, females. Affected individuals are represented by solid symbols.
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Table 1
Clinical features of family members with PRKAG2 mutation.
Case Sex Age of onset
(years)
ECG/HOLTER UCG Therapy/prognosis
II:2 F – Sinus bradycardia, Morse I type AVB, CRBBB IVS 2.8 cm EF 40.1% Symptomatic treatment, deceased
II:5  M 35 Sinus bradycardia, III◦AVB, WPW,  paroxysmal atrial
tachycardia
IVS 2.28 cm EF 56.4% PPM, deceased
II:7  M – – – PPM, deceased
II:10  F 38 Sinus bradycardia, sinus bradycardia, short PR interval,
Morse I type AVB, AF
IVS 1.3 cm Untreated
III:1(proband) M 34 Sinus bradycardia, Morse II type AVB, AF IVS 3.2 cm EF 28.7% PPM
III:4  F 24 Sinus bradycardia, sinus bradycardia, short PR interval,
CRBBB,AF
IVS 1.3 cm PPM
III:6  F 41 Sinus bradycardia, sinus bradycardia, short PR interval,
paroxysmal atrial tachycardia, AF, intermittency
intra-atrial block
IVS 1.3 cm Symptomatic treatment
III:7  M 28 Sinus bradycardia, WPW,  paroxysmal tachycardia IVS 2.26 cm Untreated
III:24 M 33 Sinus bradycardia, atrial premature Normal Symptomatic treatment
III:28  M 26 Sinus bradycardia, CRBBB Normal –
IV:3  F 16 Sinus rhythm, IRBBB Normal –
IV:4  M 18 WPW  IVS 1.9 cm Sudden death at 21
IV:12  F – Sinus arrhythmia, IRBBB Normal –
E ite sy
i aker;
2
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n
G
I
o
F
tCG, electrocardiogram; AVB, atrio-ventricular block; WPW,  Wolff–Parkinson–Wh
ncomplete right bundle branch block; EF, ejection fraction; PPM, permanent pacem
98 (Fig. 3B). Direct DNA sequencing of a simple hypertrophic
ardiomyopathy family and 100 unrelated healthy individuals did
ot show this mutation. The evolutionary conservation of PRKAG2
ly100 residue between ﬁsh and humans is shown in Fig. 3C.ntracellular localization of mutant PRKAG2 proteins
To explore the effects of G100S mutation in non-CBS
f PRKAG2, we ﬁrst examined whether and where mutant
ig. 2. (A) Echocardiographic apical four-chamber view demonstrates a normal posterior 
ract  pressure gradient is 18 mmHg. (C) Archived electrocardiogram of the proband demondrome; AF, atrial ﬁbrillation; CRBBB, complete right bundle branch block; IRBBB,
 IVS, interventricularseptal thickness.
PRKAG2 proteins were expressed in CCL13 cells by transfect-
ing the PRKAG2 cDNAs into CCL13 cells. The most common
mutation (R302Q) in CBS was  used as a positive control. West-
ern blot analysis using whole cell lysates revealed that two
mutants and WT  were expressed in CCL13 cells at comparable
levels (Fig. 4). Immunocytochemistry using anti-PRKAG2 anti-
body revealed that transfected WT,  RQ, and GS were diffusely
localized in both the cytoplasm and nucleus of CCL13 cells
(Fig. 5).
wall and septal hypertrophy. (B) Ultrasonic spectrum shows left ventricular outﬂow
nstrates ventricular preexcitation.
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Fig. 3. PRKAG2 mutation in affected patients detected by DNA sequencing. (A) Sequencing analysis showed a Gly100Ser amino acid substitution in the protein product.
( t nucl
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D
R
c
o
C
t
F
c
p
CB)  Sequence data from PRKAG2 exon 3 showing a heterozygous G → A transition a
onservation of PRKAG2 Gly100 residue between ﬁsh (accession number: XP 6967
ANMAN7.0.
eduction in AMPK concentration in PRKGA2 mutant-expressing
ellsAMPK is an important protein kinase found in all eukary-
tic cells. AMPK concentrations of CCL13/WT, CCL13/GS, and
CL13/RQ cells were measured by ELISA after adding AICAR at
wo concentrations. AMPK concentration was signiﬁcantly elevated
ig. 4. Western blot analyses using antibody speciﬁc for PRKAG2 reacted with whole
ell  lysates from PRKAG2-transfected and non-transfected CCL13 cells. The PRKAG2
rotein is of 63 kDa. GAPDH serves as a loading control. Lane 1, CCL13/WT; lane 2,
CL13/GS; lane 3, CCL13/RQ; lane 4, non-TG CCL13.eotide 298. Arrow heads mark the site of the base alteration. (C) The evolutionary
nd human (accession number: NP 057287.2), which was constructed by using the
corresponding to increased AICAR concentrations in all groups
(Fig. 6). With or without AICAR, AMPK concentrations of CCL13/GS
and CCL13/RQ cells were signiﬁcantly decreased compared to that
of CCL13/WT cells. In addition, CCL13/GS cells exhibited a signiﬁ-
cant difference in AMPK concentration compared with CCL13/RQ
cells. These ﬁndings indicate that AMPK concentration can repre-
sent AMPK activity to a suitable degree. Moreover, PRKAG2 G100S
and R302Q degraded the AMPK activity of CCL13 cells, whereas the
inﬂuence of PRKAG2 G100S to AMPK activity was  less than that of
PRKAG2 R302Q.
Accumulation of glycogen in PRKGA2 mutant-expressing cells
Previous studies have reported that some missense mutations
(N488I, R302Q, R531G, and T400N) in CBS of the PRKAG2 gene
cause a marked accumulation of cardiac glycogen [5,11,14–16]. To
determine whether the PRKAG2 mutation in non-CBS results in
glycogen accumulation, CCL13/WT, CCL13/GS, and CCL13/RQ cells
were analyzed by staining them with PAS reagent. Increased glyco-
gen accumulation was detected in CCL13/GS and CCL13/RQ cells,
compared to CCL13/WT cells (Fig. 7).
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Fig. 5. Immunocytochemistry using anti-PRKAG2 antibody revealed that transfected WT,  RQ, and GS are diffusely localized in the cytoplasm and nucleus of transfected CCL13
cells.
Fig. 6. Non-5-aminoimidazole-4-carboxamide-1--d-ribofuranoside (AICAR)-stimulated and AICAR-stimulated AMP-activated protein kinase (AMPK) levels in CCL13 cells.
AMPK concentration was measured by enzyme-linked immunosorbent assay after adding AICAR at two concentrations. AICAR induces a dose-dependent increase in AMPK
concentration at 60 min. Data are expressed as mean ± SEM of three experiments. *p < 0.05, **p  < 0.01 vs. control levels; #p < 0.05 vs. 0.5 mM AICAR group.
 CCL1
P
i
r
d
(Fig. 7. Periodic acid-Schiff (PAS) staining of every group of CCL13 cells. (A)
roliferation of CCL13 cells in response to PRKAG2 mutations
Next, we sought to determine whether gene mutations can
nﬂuence CCL13 cell proliferation following addition of AICAR. The
esults showed AICAR did not elicit mutation-related increase or
ecrease in CCL13 cell proliferation after 30 min, 90 min, and 24 h
Fig. 8).3/GS cells; (B) CCL13/RQ cells; and (C) CCL13/WT cells. Scale bar = 200 m.
Discussion
In this study, we  describe a Chinese family with a new heterozy-
gous PRKAG2 mutation (G100S) mapped to exon 3, which manifests
ventricular preexcitation, severe conduction system abnormalities,
and cardiac hypertrophy. Moreover, we  also introduce a cell model
of PRKAG2 cardiac syndrome caused by the G100S mutation. Our
B.-l. Zhang et al. / Journal of Cardiology 62 (2013) 241–248 247
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rig. 8. Impact of mutation on cell proliferation after 5-aminoimidazole-4-carboxa
elated increase or decrease in CCL13 cell proliferation at all the time points. Values
tudies in both humans and cells provide strong evidence for the
ole of PRKAG2 in the physiology of heart and the pathogenesis
f PCS, a relatively rare autosomal dominant disorder. Multiple
ines of evidence indicate that the G100S mutation in PRKAG2 on
hromosome 7p36 results in Chinese PRKAG2 cardiac syndrome.
irst, we have identiﬁed a novel heterozygous mutation, G100S
n PRKAG2, which is present in all affected individuals in the
amily, but does not exist in another simple hypertrophic cardiomy-
pathy family and 100 controls. Second, we have conﬁrmed that
xpression of PRKAG2 protein in CCL13 cells and subsequently,
he G100S mutation reduces PRKAG2 protein expression. Third,
e have demonstrated that the G100S mutation impairs PRKAG2-
ediated activity of AMPK and leads to dysregulated glycogen
etabolism in CCL13 cells. Fourth, the G100S mutation in non-CBS
omains and the R302Q mutation in CBS domains result in similar
unctional consequences although resulting in different changes in
RKAG2 protein levels. To our knowledge, our ﬁndings represent
ot only the ﬁrst mutation located in non-CBS domains of PRKAG2,
ut also the ﬁrst description of the clinical and biochemical effects
f non-CBS domains of PRKAG2.
The PRKAG2 gene has two different transcripts: PRKAG2-a, a
ull-length transcript and PRKAG2-b, a truncated transcript, which
re composed of 16 and 12 exons and span 300 kb and 80 kb in
ength, respectively [3,21,22]. These two transcripts have four iden-
ical and consecutive CBS domains, a characteristic structure of
MPK2 subunit, which tandems to form the Bateman domain.
he Bateman domain is highly conserved across species examined
o date. By overexpressing PRKAG2 gene in CCL13 cells, John et al.
emonstrated that the four tandem pairs of CBS domains in the
 subunits of AMPK form allosteric binding sites for adenosine
erivatives and provide two allosteric binding sites for AMP  and
TP [12]. Pathogenic mutations including R302Q, H383R, T400N,
nd R531G lead to an increase for binding of AMP to CBS domains
f 2. This reveals that tandem pairs of CBS domains play as a
ensor of cellular energy status. However, the function of non-CBS
omains is still unknown. One interesting feature is that the pre-
ious nine pathogenic mutations tend to occur in CBS domains,
hereas the new mutation G100S is located in non-CBS domains.
ur results show that G100S in non-CBS domains have similar but
ess mutational effects compared with R302Q in CBS domains. This
uggests that the mechanism of G100S in non-CBS domains reg-
lating AMPK activity may  be consistent with that of R302Q in
BS domains. Our results support the idea that the function of
on-CBS domains may  be similar to CBS domains. Whether the
utation in non-CBS domains indirectly changes the binding abil-ty of CBS domains to AMP  and ATP is not clear. We  speculate that
ither non-CBS domains have an ability of binding AMP  and ATP or
he mutation in this region that alters protein structure ultimately
esults in functional changes of CBS domains.1--d-ribofuranoside (AICAR) treatment. 0.5 mM AICAR did not induce mutation-
xpressed as mean ± SEM of three experiments. **p < 0.01 vs. non-TG group.
Our studies on AMPK activation or glycogen accumulation are
in good agreement with previous studies [12–15], which show
that mutations associated with hereditary diseases exhibit defec-
tive loss or decrease in AMPK activity. Consistent with our results,
marked attenuation or absent enzymatic activity associated with
the R302Q mutation in vitro has been reported. Furthermore, Scott
et al. conﬁrmed the mutation R302Q causing loss of enzymatic
activity and revealed the mechanism to the decreased binding
activity to AMP  [23]. In vivo studies by Sidhu et al. show enzy-
matic activity of AMPK is signiﬁcantly reduced, presumably owing
to the mutation disrupting the AMP  binding site, and excessive car-
diac glycogen is observed in the TGR302Q heart [14]. Further in vivo
studies by Davies et al. proposed that the R531G mutation in 2
leads to suppression of total cardiac AMPK activity secondary to
the increased glycogen accumulation in transgenic mice [24]. These
studies not only show that the primary defect of a mutant is caused
by loss of AMPK activity and increased glycogen synthesis, but also
suggest the molecular basis which provides insight into develop-
ment of ventricular preexcitation, conduction defects, and cardiac
hypertrophy. New evidence is added by our study that CCL13 cells
show increased glycogen deposition resulting from the G100S and
R302Q mutations.
Neither our results nor the above-mentioned studies [12–15]
support the previous claim [3] that the N488I mutation is asso-
ciated with increased AMPK activity. Nevertheless, the transgenic
mice overexpressing the mutation N488I manifest the phenotype
of large amounts of cardiac glycogen (30-fold above normal) accu-
mulating, which provides an anatomic explanation for ventricular
hypertrophy (because of per se glycogen accumulation) and ventri-
cular preexcitation (because of disruption of the annulus ﬁbrosis by
glycogen-engorged myocytes). The authors suggest the mechanism
of increased absorption of glucose. The effect of three mutations
(R302Q, N488I, and R531G mutations) on AMPK activity remains
controversial. Further in vivo studies [16] show that there is a
biphasic response of AMPK activity to the T400N mutation in
PRKAG2 in the TGT400N murine model, providing an explanation
for the discrepant ﬁndings concerning AMPK activity in previous
studies.
An important subsidiary ﬁnding of our study was that the G100S
and R302Q mutations did not cause increase of CCL13 cell apopto-
sis compared with WT  PRKAG2 gene, in the presence or absence
of AMPK activator—AICAR. In contrast, previous studies suggest
that apoptosis could be induced by AMPK, which induces apoptosis
of pancreatic -cells though c-myc or c-Jun N-kinase and posti-
cus caspase pathway, and apoptosis of neuroblastoma by caspase
pathway, after activation by AICAR [25–27]. Our  results indicate
that AMPK, by some speciﬁed mechanism, may  exert inﬂuence
on the growth of a few phyletic cells, rather than all types of
cells.
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A second subsidiary ﬁnding from our study was that no inﬂu-
nce of the G100S and R302Q mutations in PRKAG2 on intracellular
ocation of PRKAG2 protein was observed, although the mutations
mpair AMPK activation. Taken together, our data strongly suggest
hat the role of the 2 subunit regulating AMPK activity is not asso-
iated with the location of the protein in cells and indicate that
he mutation of PRKAG2 does not affect the ability of permeating
esoplasts when expressed in CCL13 cells.
In summary, the novel missense mutation G100S in PRKAG2
ay  participate in the regulation of cells’ vital movement through
he AMPK signal pathway and is responsible for the Chinese PCS.
he results also support the notion that PCS is a glycogen stor-
ge disease. Interestingly, Light et al. [28] suggest that cardiac
oltage-gated sodium channels are regulated by overexpression
f a constitutively active AMPK mutant and propose that sodium
hannels may  be substrates of AMPK, possibly contributing to
evelopment of arrhythmia in PCS. Therefore, other distinct signal
athways may  exist, which remains to be determined.
However, there still exist some limitations in our study. This
xperiment was performed to preliminarily explain the biological
ffect of PRKAG2 G100S mutation and further in vivo experiments
hould be carried out; we should further persuade the family mem-
ers to obtain cardiac biopsy samples and detect the glycogen
torage; a qualitative change in PRKAG2 protein should be further
onﬁrmed.
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